New Saliva Test for Early Prostate Cancer Detection Promises to Revolutionize Screening

A groundbreaking study unveiled at the American Society of Clinical Oncology meeting suggests that a simple at-home saliva test could significantly improve prostate cancer detection, potentially saving thousands of lives globally.

Researchers from the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust presented findings that highlight this saliva test as a potential game-changer in the fight against prostate cancer. The test, which is easy to use and affordable, could serve as a more accurate alternative to the current standard blood test for identifying high-risk individuals.

The study involved over 6,142 men aged 55-69 and utilized a polygenic risk score based on genetic variations linked to prostate cancer. This approach enabled researchers to pinpoint 588 men at the highest risk for further screening. The new method aims to facilitate earlier detection of high-risk cases while reducing unnecessary anxiety and potential side effects for men at lower risk.

According to the study, the saliva test produces fewer false positives compared to the standard blood test and shows greater efficacy in detecting aggressive cancers. While the current blood test measures prostate-specific antigen (PSA) levels, which can be unreliable, the saliva test identified prostate cancer in 40 percent of men with high scores, versus only 25 percent for the PSA test. This improved accuracy could lead to earlier intervention for aggressive cancers, enhancing treatment outcomes.

Professor Kristian Helin, chief executive of the Institute of Cancer Research, emphasized the urgency of adopting improved screening methods: “Cancers that are picked up early are much more likely to be curable, and with prostate cancer cases set to double by 2040, we must have a programme in place to diagnose the disease early. The current PSA test can cause men to undergo unnecessary treatments and, more worryingly, it’s missing men who do have cancer. We urgently need an improved test to screen for the disease.”